Download PDF
Drug Res (Stuttg) 2022; 72(03): 123-130
DOI: 10.1055/a-1697-5365
Review

Phytoconstituents in the Management of Covid-19: Demystifying the Fact

Phytoconstituents Potential in COVID-19
Md. Abul Barkat
1   Department of Pharmaceutics, College of Pharmacy, University of Hafr Al-Batin, KSA
,
Pawan Kaushik
2   Institute of Pharmaceutical Sciences, Kurukshetra University, Kurukshetra, Haryana, India
,
Harshita Abul Barkat
1   Department of Pharmaceutics, College of Pharmacy, University of Hafr Al-Batin, KSA
3   Dermatopharmaceutics Research Group, Faculty of Pharmacy, International Islamic University Malaysia, Kuantan, Pahang, Malaysia
,
Mohammad Idreesh Khan
4   Department of Clinical Nutrition, College of Applied Health Sciences in Arras, Qassim University, KSA
,
Hazrina Ab Hadi
3   Dermatopharmaceutics Research Group, Faculty of Pharmacy, International Islamic University Malaysia, Kuantan, Pahang, Malaysia
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

The 2019-nCoV (COVID-19; novel coronavirus disease-2019) outbreak is caused by the coronavirus, and its continued spread is responsible for increasing deaths, social and economic burden. COVID-19 created a chaotic situation worldwide and claimed the lives of over 5,027,183 and 248,467,363 confirmed cases have been reported so far as per the data published by WHO (World Health Organization) till 5th November 2021. Scientific communities all over the world are toiling to find a suitable therapeutic drug for this deadly disease. Although till date no promising drug has been discovered for this COVID-19. However, as per the WHO, over 102 COVID-19 vaccines are in clinical development and 185 in pre-clinical development. Naturally occurring phytoconstituents possess considerable chemical richness in the form of anti-viral and anti-parasitic potential and have been extensively exploited for the same globally. Still, phytomedicine-based therapies are considered as the best available treatment option to minimize and treat the symptoms of COVID-19 because of the least possible side effects compared to synthetic drugs recommended by the physicians/clinicians. In this review, the use of plant chemicals as a possible therapeutic agent for severe acute respiratory syndrome coronavirus 2 (SARS CoV2) is highlighted with their proposed mechanism of action, which will prove fruitful and effective in finding a cure for this deadly disease.

Key words

Coronavirus - COVID-19 - Phytochemicals - SARS-CoV2 - Phytomedicine - clinical and pre-clinical development


Publication History

Received: 09 August 2021

Accepted: 08 November 2021

Article published online:
03 January 2022

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Chojnacka K, Witek-Krowiak A, Skrzypczak D. et al. Phytochemicals containing biologically active polyphenols as an effective agent against Covid-19-inducing coronavirus. J Funct Foods 2020; 73: 104146
    CrossrefPubMedGoogle Scholar
  • 2 Sohrabi C, Alsafi Z, O'Neill N. et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg 2020; 76: 71-76
    CrossrefPubMedGoogle Scholar
  • 3 https://covid19.who.int/
    PubMed
  • 4 Wu A, Peng Y, Huang B. et al. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe 2020; 27: 325-328 DOI: 10.1016/j.chom.2020.02.001.
    CrossrefPubMedGoogle Scholar
  • 5 Yang Y, Peng F, Wang R. et al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. [published correction appears in J Autoimmun. 2020;111:102487]. J Autoimmun 2020; 109: 102434 DOI: 10.1016/j.jaut.2020.102434.
    CrossrefPubMedGoogle Scholar
  • 6 Lu G, Wang Q, Gao GF. Bat-to-human: spike features determining 'host jump' of coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends Microbiol 2015; 23: 468-478 DOI: 10.1016/j.tim.2015.06.003.
    CrossrefPubMedGoogle Scholar
  • 7 Paraskevis D, Kostaki EG, Magiorkinis G. et al. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infect Genet Evol 2020; 79: 104212 DOI: 10.1016/j.meegid.2020.104212.
    CrossrefPubMedGoogle Scholar
  • 8 https://www.who.int/health-topics/middle-east-respiratory-syndrome-coronavirus-mers#tab=tab_1
    PubMed
  • 9 Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr 2020; 87: 281-286
    CrossrefPubMedGoogle Scholar
  • 10 https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
    PubMed
  • 11 Cortegiani A, Ingoglia G, Ippolito M. et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 2020; 57: 279-283
    CrossrefPubMedGoogle Scholar
  • 12 Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 14: 72-73
    CrossrefPubMedGoogle Scholar
  • 13 Yao TT, Qian JD, Zhu WY. et al. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option. J Med Virol 2020; 92: 556-563
    CrossrefPubMedGoogle Scholar
  • 14 Holshue ML, DeBolt C, Lindquist S. et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med 2020; 382: 929-936 DOI: 10.1056/NEJMoa2001191..
    CrossrefPubMedGoogle Scholar
  • 15 Wang M, Cao R, Zhang L. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30: 269-271 DOI: 10.1038/s41422-020-0282-0..
    CrossrefPubMedGoogle Scholar
  • 16 Khamitov RA, Loginova SIa, Shchukina VN. et al. Vopr Virusol. 2008; 53 (4): 9–13
    PubMed
  • 17 Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci trends 2020; 14: 69-71
    CrossrefPubMedGoogle Scholar
  • 18 Zhong N. Management and prevention of SARS in China. Philos Trans R Soc Lond B Biol Sci 2004; 359: 1115-1116
    CrossrefPubMedGoogle Scholar
  • 19 Yang Y, Islam MS, Wang J. et al. Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective. Int J Biol Sci 2020; 16: 1708
    CrossrefPubMedGoogle Scholar
  • 20 Wu XV, Dong Y, Chi Y. et al. Traditional Chinese Medicine as a complementary therapy in combat with COVID-19-A review of evidence-based research and clinical practice. J Adv Nurs 2021; 77: 1635-1644
    CrossrefPubMedGoogle Scholar
  • 21 Cinatl J, Morgenstern B, Bauer G. et al. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 2003; 361: 2045-2046
    CrossrefPubMedGoogle Scholar
  • 22 Chen F, Chan KH, Jiang Y. et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol 2004; 31: 69-75
    CrossrefPubMedGoogle Scholar
  • 23 Luo E, Zhang D, Luo H. et al. Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID-19): an empirical study from Wuhan, Hubei Province, China. Chin Med 2020; 15: 1-3
    CrossrefPubMedGoogle Scholar
  • 24 https://www.ayush.gov.in/docs/125.pdf
    PubMed
  • 25 https://clinicaltrials.gov/ct2/show/NCT04323332
    PubMed
  • 26 Adithya J, Nair B, Aishwarya TS. et al. The Plausible Role of Indian Traditional Medicine in Combating Corona Virus (SARS-CoV 2): A Mini-Review. Curr Pharm Biotechnol 2021; 22: 906-919
    CrossrefPubMedGoogle Scholar
  • 27 https://www.afro.who.int/news/who-supports-scientifically-proven-traditional-medicine? gclid=Cj0KCQjw2PP1BRCiARIsAEqv-pT8RC78wAq_uLDX-1lQJUzcSKYNEIbZJdxoV-H1YFvh0KJkoBedpeKYaAjgcEALw_wcB
    PubMed
  • 28 Lin LT, Hsu WC, Lin CC. Antiviral natural products and herbal medicines. J Tradit Complement Med 2014; 4: 24-35
    CrossrefPubMedGoogle Scholar
  • 29 Pang J, Wang MX, Ang IY. et al. Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): a systematic review. Journal of clinical medicine 2020; 9: 623
    CrossrefPubMedGoogle Scholar
  • 30 Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci trends 2020; 14: 69-71
    CrossrefPubMedGoogle Scholar
  • 31 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395: 497-506
    CrossrefPubMedGoogle Scholar
  • 32 Shi H, Han X, Jiang N. et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis 2020; 20: 425-434
    CrossrefPubMedGoogle Scholar
  • 33 Jin Y, Yang H, Ji W. et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020; 12: 372
    CrossrefPubMedGoogle Scholar
  • 34 Wu F, Zhao S, Yu B. et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020; 580: E7
    CrossrefPubMedGoogle Scholar
  • 35 Zhou P, Yang XL, Wang XG. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579: 270-273
    CrossrefPubMedGoogle Scholar
  • 36 Shereen MA, Khan S, Kazmi A. et al. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res 2020; 24: 91-98
    CrossrefPubMedGoogle Scholar
  • 37 Xu X, Chen P, Wang J. et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci 2020; 63: 457-460
    CrossrefPubMedGoogle Scholar
  • 38 Wan Y, Shang J, Graham R. et al. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol 2020; 94: e00127-20
    PubMedGoogle Scholar
  • 39 Cherian SS, Agrawal M, Basu A. et al. Perspectives for repurposing drugs for the coronavirus disease 2019. Indian J Med Res 2020; 151: 160-171
    CrossrefPubMedGoogle Scholar
  • 40 Lung J, Lin YS, Yang YH. et al. The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase. J Med Virol 2020; 92: 693-697
    CrossrefPubMedGoogle Scholar
  • 41 Sampangi-Ramaiah MH, Vishwakarma R, Shaanker RU. Molecular docking analysis of selected natural products from plants for inhibition of SARS-CoV-2 main protease. Current Science 2020; 118: 1087-1092
    CrossrefPubMedGoogle Scholar
  • 42 Goswami D, Kumar M, Ghosh SK. et al. Natural product compounds in Alpinia officinarum and ginger are potent SARS-CoV-2 papain-like protease inhibitors. chemRxiv. 2020. doi:10.26434/chemrxiv.12071997
    PubMed
  • 43 Su H, Yao S, Zhao W. et al. Discovery of baicalin and baicalein as novel, natural product inhibitors of SARS-CoV-2 3CL protease in vitro. bioRxiv. 2020. DOI:10.1101/2020.04.13.038687
    PubMed
  • 44 Sudeep HV, Gouthamchandra K, Shyamprasad K. Molecular docking analysis of Withaferin A from Withania somnifera with the Glucose regulated protein 78 (GRP78) receptor and the SARS-CoV-2 main protease. Bioinformation. 2020; 16: 411-417
    CrossrefPubMedGoogle Scholar
  • 45 Aanouz I, Belhassan A, El-Khatabi K. et al. Moroccan Medicinal plants as inhibitors against SARS-CoV-2 main protease: Computational investigations. J Biomol Struct Dyn 2021; 39: 2971-2979
    CrossrefPubMedGoogle Scholar
  • 46 Teli DM, Shah MB, Chhabria MT. In silico Screening of Natural Compounds as Potential Inhibitors of SARS-CoV-2 Main Protease and Spike RBD: Targets for COVID-19. Front Mol Biosci 2021; 7: 599079
    CrossrefPubMedGoogle Scholar
  • 47 Das S, Sarmah S, Lyndem S. et al. An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study. J Biomol Struct Dyn. 2020; 1-11
    PubMed
  • 48 Enmozhi SK, Raja K, Sebastine I. et al. Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach. J Biomol Struct Dyn 2020; 39: 1–7
    PubMed
  • 49 Umar HI, Josiah SS, Saliu TP. et al. In-silico analysis of the inhibition of the SARS-CoV-2 main protease by some active compounds from selected African plants. J Taibah Univ Med Sci 2021; 16: 162-176
    PubMedGoogle Scholar
  • 50 Gyebi GA, Ogunro OB, Adegunloye AP. et al. Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CLpro): an in silico screening of alkaloids and terpenoids from African medicinal plants. J Biomol Struct Dyn 2021; 39: 3396-3408
    PubMedGoogle Scholar
  • 51 Shaghaghi N. Molecular docking study of novel COVID-19 protease with low risk terpenoides compounds of plants. ChemRxiv 1. 2020. https://doi.org/10.26434/chemrxiv.11935722.v1
    PubMed
  • 52 Borse S, Joshi M, Saggam A. et al. Ayurveda botanicals in COVID-19 management: An in silico multi-target approach. PLoS One 2021; 16: e0248479
    CrossrefPubMedGoogle Scholar
  • 53 Tahir Ul Qamar M, Alqahtani SM, Alamri MA. et al. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. J Pharm Anal 2020; 10: 313-319
    CrossrefPubMedGoogle Scholar
  • 54 Elfiky AA. Natural products may interfere with SARS-CoV-2 attachment to the host cell. J Biomol Struct Dyn. 2020; 1-10
    PubMed
  • 55 Sinha SK, Shakya A, Prasad SK. et al. An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets. J Biomol Struct Dyn. 2020; 1-12
    PubMed
  • 56 Ubani A, Agwom F, Shehu NY. et al. Molecular Docking Analysis Of Some Phytochemicals On Two SARS-CoV-2 Targets. bioRxiv. 2020. https://doi.org/10.1101/2020.03.31.017657
    PubMed
  • 57 Rathinavel T, Palanisamy M, Palanisamy S. et al. Phytochemical 6-Gingerol–A promising Drug of choice for COVID-19. Int J Adv Sci Eng 2020; 6: 1482-1489
    CrossrefPubMedGoogle Scholar
  • 58 Wahedi HM, Ahmad S, Abbasi SW. Stilbene-based natural compounds as promising drug candidates against COVID-19. J Biomol Struct Dyn 2020; 39: 1–10
    PubMed
  • 59 Abdelli I, Hassani F, Bekkel Brikci S. et al. In silico study the inhibition of angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from Western Algeria. J Biomol Struct Dyn 2021; 39: 3263-3276
    PubMedGoogle Scholar
  • 60 Joshi T, Joshi T, Sharma P. et al. In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking. Eur Rev Med Pharmacol Sci 2020; 24: 4529-4536
    CrossrefPubMedGoogle Scholar
  • 61 Thuy BT, My TT, Hai NT. et al. Investigation into SARS-CoV-2 resistance of compounds in garlic essential oil. ACS omega 2020; 5: 8312-8320
    CrossrefPubMedGoogle Scholar
  • 62 Hilgenfeld R. From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. The FEBS journal 2014; 281: 4085-4096
    CrossrefPubMedGoogle Scholar
  • 63 Hoffmann M, Kleine-Weber H, Schroeder S. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181: 271-280 .e8
    CrossrefPubMedGoogle Scholar
  • 64 Kuba K, Imai Y, Rao S. et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005; 11: 875-879
    CrossrefPubMedGoogle Scholar
  • 65 Belouzard S, Millet JK, Licitra BN. et al. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses. 2012; 4: 1011-1033
    CrossrefPubMedGoogle Scholar
  • 66 Abubakar MB, Usman D, El-Saber Batiha G. et al. Natural Products Modulating Angiotensin Converting Enzyme 2 (ACE2) as Potential COVID-19 Therapies. Front Pharmacol 2021; 12: 629935
    CrossrefPubMedGoogle Scholar
  • 67 Wei X, Zhu X, Hu N. et al. Baicalin attenuates angiotensin II-induced endothelial dysfunction. Biochem Biophys Res Commun 2015; 465: 101-107
    CrossrefPubMedGoogle Scholar
  • 68 Wang Z, Wang S, Zhao J. et al. Naringenin Ameliorates Renovascular Hypertensive Renal Damage by Normalizing the Balance of Renin-Angiotensin System Components in Rats. Int J Med Sci 2019; 16: 644-653 Published 2019 May 7 DOI: 10.7150/ijms.31075.
    CrossrefPubMedGoogle Scholar
  • 69 Liu H, Jiang Y, Li M. et al. Ginsenoside Rg3 Attenuates Angiotensin II-Mediated Renal Injury in Rats and Mice by Upregulating Angiotensin-Converting Enzyme 2 in the Renal Tissue. Evid Based Complement Alternat Med 2019; 2019: 6741057
    PubMedGoogle Scholar
  • 70 Zi C, Zhang N, Yang L. et al. Discovery of a potent angiotensin converting enzyme 2 inhibitor from Chinese Medicinal and Edible Plant via Docking-based Virtual Screening. Research Square; 2020. DOI: 10.21203/rs.3.rs-32515/v1
    PubMed
  • 71 Ohashi H, Watashi K, Saso W. et al. Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. iScience 2021; 24: 102367 DOI: 10.1016/j.isci.2021.102367.
    CrossrefPubMedGoogle Scholar
  • 72 Takahashi S, Yoshiya T, Yoshizawa-Kumagaye K. et al. Nicotianamine is a novel angiotensin-converting enzyme 2 inhibitor in soybean. Biomed Res 2015; 36: 219-224 DOI: 10.2220/biomedres.36.219.
    CrossrefPubMedGoogle Scholar